

**Wanbury Limited**

**Regd. Office :** BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
+91-22-7196 3222  
CIN L51900MH1988PLC048455  
Email : info@wanbury.com  
Website : www.wanbury.com

June 9, 2026

BSE Limited P.J. Towers, Dalal Street Mumbai - 400 001.  <b>Script Code: 524212</b>	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.  <b>Script Code: WANBURY</b>
--	--

Dear Sir/Madam,

**Sub: Press Release on launch of new APIs**

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Wanbury Limited, a leading pharmaceutical company with a good legacy in domestic and global API markets and branded formulations today announced the Wanbury expanded regulatory submission for launch of new Active Pharmaceutical Ingredients (APIs).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore. The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

This is for your information and record.

**Thanking you.**

**Yours faithfully,  
For Wanbury Ltd**



**Jitendra J. Gandhi  
Company Secretary**